In an prospective observational study of patients with inflammatory bowel disease with oral thrush, the treatment of fluconazole (orogastrointestinal therapy), but not nystatin (oral therapy), led to intestinal mycobiome and microbiome alterations and improved disease activity at 8 weeks of follow-up.